Advisor to the Board

Role: Chief Scientific Advisor (Clinical Trials & Wound-Healing)

Summary

An experienced ex-Chief Scientific Officer experienced in clinical areas relating to wound-care is sought to guide an oral metabolic therapy for chronic leg-ulcer healing from first-in-patient data through regulatory submission (border-line medicine) and NHS reimbursement.

The mandate begins as low-commitment advisory and, based on your situation and appetite, could evolve into a fractional or full CSO post once pilot results and seed funding unlock the next scale phase. If a hands-on role isn’t right for you or you couldn’t commit time, you’d be instrumental in selecting a long-term CSO hire.

The business

The company is concluding a 20-patient UK pilot; in 12 weeks the results should underpin a £0.25-1m SEIS/EIS raise, followed by a 200-patient pivotal study and a further £2m+ round to support a borderline-medicine filing. Large multinational consumer-health groups already sell oral products targeting wound support, yet none are prescribable because they lack controlled clinical evidence. This programme aims to become the first reimbursable option by pairing layered IP with rigorous UK data. 3rd party in vitro research (existing, i.e. not commissioned) supports type 2 collagen increase, but the team are targeting a different use case for type 1 and type 2.

Its trials are being carried out by Pioneer Wound Care, the country’s largest wound-care provider, delivering high-quality data regulators and payers trust. The team believes the trial will succeed because robust third-party studies already show the lead amino-acid drives collagen type II formation; their proprietary formulation targets additional pathways and the upcoming trials will measure its impact on wound-relevant collagen types I and III.

They expect to reapply for patents a total of three times with each patent taking around 1 year, covering their 5 compounds:

• Pathway 1 compound (current application)
• Multiple compounds, 1 pathway
• Multiple compounds multiple pathways, each time data should

Key people

• The founder CEO:self-financed patent prosecution and early modelling after a decade launching longevity-nutrition ventures. Biochemistry academic background.
• Chair:serial bio-entrepreneur (founder/CSO) of an established marine-collagen-focused healthcare business (external application - currently going through FDA approval, fully approved in UK) provides deep skin-related clinical trial and entrepreneurial expertise. The business is highly successful and an exit for a very significant amount could be expected post FDA approval.
• Board Advisor:practising tissue-viability specialist and Clinical Trials Lead at Pioneer Wound Care, the UK’s largest wound-care provider. He co-designs protocols, manages investigator teams and oversees service-evaluation governance, ensuring the 20- and 200-patient studies meet MHRA and NICE data standards. His dual role gives the company day-to-day clinical-operations oversight while providing immediate feedback from frontline wound-care settings, markedly reducing execution risk.
• Board advisor:Pharmacy & Population Health Management at an NHS ICB Trust

Value-add

Your key value-add will be minimising execution risk of progressing through the various clinical trials, including the support for its MHRA approval as a border-line medicine, and eventually FDA approval. CSO-specific knowledge provided by the chair, but this is not a long term solution given their other time commitments re main venture.

Compensation

Weighted towards growth shares, with a cash component activated once the patent is granted, the 20-patient study reports positively and the initial SEIS tranche closes; terms to be agreed.

Process

An informal introductory call with the founder assesses mutual fit, followed by focussed discussions with the chair and clinical team before any offer is extended.